Renal Cell Carcinoma: Focus on Safety and Efficacy of Temsirolimus

被引：45

作者：

Hadoux, Julien ^{[1
]}

Vignot, Stephane ^{[2
]}

Rouge, Thibault De La Motte ^{[2
]}

机构：

[1] Grp Hosp Pitie Salpetriere, Serv Radiotherapie, 47-83 Blvd Hop, F-75651 Paris 13, France

[2] Grp Hosp Pitie Salpetriere, Med Oncol Serv, F-75651 Paris 13, France

来源：

CLINICAL MEDICINE INSIGHTS-ONCOLOGY | 2010年 / 4卷

关键词：

clear cell carcinoma; temsirolimus; mTOR; rapamycin; safety; efficacy;

D O I：

10.4137/CMO.S4482

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Metastatic renal cell carcinoma has harboured a poor prognosis for decades with immunotherapy being the only available therapy with high toxicity and modest effect. Dependance of renal cell carcinoma oncogenesis on the mTOR pathway has led to clinical development of temsirolimus in this setting. This sirolimus derivative has shown clinical efficacy in monotherapy for poor-risk renal cell carcinoma leading to an overall survival of 10.8 months in the pivotal phase III trial of this agent. Its specific adverse events consist of metabolic dysregulation (hyperlipemia, hyperglycemia), mucositis, rash and pneumonitis which can be severe and need careful monitoring and management. In this review, we will discuss of the clinical development of this molecule, its efficacy, its safety profile and future perspectives.

引用

页码：143 / 154

页数：12

共 48 条

[41] Peralba JM, 2003, CLIN CANCER RES, V9, P2887
[42] Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors
Punt, CJA
Boni, J
Bruntsch, U
Peters, M
Thielert, C
[J]. ANNALS OF ONCOLOGY, 2003, 14 (06) : 931 - 937
[43] Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer
Raymond, E
Alexandre, J
Faivre, S
Vera, K
Materman, E
Boni, J
Leister, C
Korth-Bradley, J
Hanauske, A
Armand, JP
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) : 2336 - 2347
[44] Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206
Rini, Brian I.
Halabi, Susan
Rosenberg, Jonathan E.
Stadler, Walter M.
Vaena, Daniel A.
Archer, Laura
Atkins, James N.
Picus, Joel
Czaykowski, Piotr
Dutcher, Janice
Small, Eric J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) : 2137 - 2143
[45] Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
Rini, Brian I.
Halabi, Susan
Rosenberg, Jonathan E.
Stadler, Walter M.
Vaena, Daniel A.
Ou, San-San
Archer, Laura
Atkins, James N.
Picus, Joel
Czaykowski, Piotr
Dutcher, Janice
Small, Eric J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (33) : 5422 - 5428
[46] Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
Thomas, GV
Tran, C
Mellinghoff, IK
Welsbie, DS
Chan, E
Fueger, B
Czernin, J
Sawyers, CL
[J]. NATURE MEDICINE, 2006, 12 (01) : 122 - 127
[47] MTOR-targeted therapy of cancer with rapamycin derivatives
Vignot, S
Faivre, S
Aguirre, D
Raymond, E
[J]. ANNALS OF ONCOLOGY, 2005, 16 (04) : 525 - 537
[48] Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016

← 1 2 3 4 5 →